Tag Archives: obesity pharmacotherapy

GLP-1 receptor agonists have transformed diabetes and obesity treatment, yet safety questions still surface in clinic visits. One concern continues to appear in patient discussions: thyroid cancer risk. The topic often traces back to early rodent studies that triggered boxed warnings for medullary thyroid carcinoma (MTC). However, clinicians today rely …

The expanding use of GLP-1 receptor agonists for type 2 diabetes and obesity has transformed metabolic care. However, growing awareness of the potential gallbladder risks associated with GLP-1 therapy has prompted clinicians to take a closer look at hepatobiliary safety. Rapid weight loss and altered bile composition during treatment may …